Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience

Objective: To investigate whether balloon-occluded transcatheter arterial chemoembolization (b-TACE) can produce a more dense accumulation of iodized oil in various stages of hepatocellular carcinoma (HCC), from single to uncountable, to overcome inferior local control. Materials and Methods: We studied 27 patients with HCC, including single to uncountable multiple lesions, who underwent b-TACE between August 2013 and April 2015. Dynamic CT was performed at baseline and 1-3 months after b-TACE. The treatment effect (TE) after b-TACE was evaluated using the Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan. Results: In the countable HCC group, contrast-enhanced CT demonstrated RECICL TE4 in 43.8% (14/32), TE3 in 12.5% (4/32), TE2 in 37.5% (12/32), and TE1 in 6.3% (2/32) of patients. For the TACE-naïve cohort, the objective response rate was 52.9%. The objective response rate was 60% for the previously TACE-treated cohort. In the uncountable multiple HCC group, the objective response rate was 0% (0/10), with progressive disease in 90% (9/10) of patients. Conclusion: Our observations suggested that b-TACE did not reduce the efficacy of retreatment for HCC with an insufficient outcome from conventional TACE, but it could not improve the efficacy of treatment for uncountable multiple HCCs.

[1]  Yoshinobu Yamamoto,et al.  Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  S. Kakizaki,et al.  Safety and efficacy of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  M. Kudo.  Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan , 2015, Liver Cancer.

[4]  M. Kudo,et al.  Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update , 2014, Oncology.

[5]  Y. Imai,et al.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.

[6]  M. Yoshikawa,et al.  Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization , 2014, Oncology.

[7]  J. Raoul,et al.  How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective , 2014, Liver Cancer.

[8]  M. Peck‐Radosavljevic.  Drug Therapy for Advanced-Stage Liver Cancer , 2014, Liver Cancer.

[9]  T. Murakami,et al.  Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography , 2014, Liver Cancer.

[10]  Joong-Won Park,et al.  Clinical Trials of Combined Molecular Targeted Therapy and Locoregional Therapy in Hepatocellular Carcinoma: Past, Present, and Future , 2014, Liver Cancer.

[11]  H. Ueno,et al.  A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis , 2013, Cancer Chemotherapy and Pharmacology.

[12]  N. Takahashi,et al.  Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon-occluded Arterial Stump Pressure , 2013, CardioVascular and Interventional Radiology.

[13]  M. Kudo,et al.  Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[14]  M. Kudo,et al.  Therapeutic Response Assessment of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Ultrasonography, CT and MR Imaging , 2013, Oncology.

[15]  T. Yamashita.  Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy. , 2012, Clinical drug investigation.

[16]  R. Lencioni.  Chemoembolization in Patients with Hepatocellular Carcinoma , 2012, Liver Cancer.

[17]  M. Makuuchi,et al.  Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version , 2011, Digestive Diseases.

[18]  M. Carpenzano,et al.  Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas , 2011, Hepatology.

[19]  T. Livraghi,et al.  Is it time to reconsider the BCLC/AASLD therapeutic flow‐chart? , 2010, Journal of surgical oncology.

[20]  M. Makuuchi,et al.  Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version) , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[21]  M. Kudo,et al.  Hepatic Arterial Infusion Chemotherapy Using Low-Dose 5-Fluorouracil and Cisplatin for Advanced Hepatocellular Carcinoma , 2010, Oncology.

[22]  Kinuyo Hatanaka,et al.  Combination Therapy with S-1 and Pegylated Interferon Alpha for Advanced Hepatocellular Carcinoma , 2008, Oncology.

[23]  F. Farinati,et al.  Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness , 2008, The American Journal of Gastroenterology.

[24]  Y. Takeda,et al.  Interferon‐α and 5‐fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules , 2007, Cancer.

[25]  E. Cholongitas,et al.  Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies , 2007, CardioVascular and Interventional Radiology.

[26]  M. Makuuchi,et al.  Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. , 2006, Gastroenterology.

[27]  M. Omata,et al.  Combination therapy of intraarterial 5‐fluorouracil and systemic interferon‐alpha for advanced hepatocellular carcinoma with portal venous invasion , 2006, Cancer.

[28]  M. Kudo,et al.  Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography. , 2003, AJR. American journal of roentgenology.

[29]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[30]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[31]  K. Sung,et al.  Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization 1 , 2002, Journal of gastroenterology and hepatology.

[32]  M. Al-Ahwal,et al.  Chemoembolization in hepatocellular carcinoma. , 1998, Saudi medical journal.

[33]  J. Bruix,et al.  Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution , 1998, Hepatology.

[34]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .